Related Experiment Videos
National cooperative group trials.
Robert S Dipaola1, Ian M Thompson
1Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA. dipaolrs@umdnj.edu
Urology
|May 12, 2005
Summary
High-priority prostate cancer clinical trials are crucial for advancing treatment. Improving patient enrollment in these systemic therapy studies is essential for better cancer management and outcomes.
Area of Science:
- Oncology
- Clinical Trials
- Prostate Cancer Management
Background:
- Critical questions remain in prostate cancer management, necessitating further research.
- Systemic therapies, including chemotherapy and novel targeted agents, require investigation across all disease stages.
- Accrual to national phase 3 clinical trials for prostate cancer has been insufficient.
Purpose of the Study:
- To review ongoing and planned national cooperative group clinical trials in prostate cancer.
- To identify and suggest practical strategies for improving clinical trial enrollment.
- To emphasize the importance of systemic therapy research in prostate cancer management.
Main Methods:
- Review of national cooperative group clinical trials for prostate cancer.
- Analysis of current and planned trial designs focusing on systemic therapies.
- Identification of barriers and facilitators to clinical trial accrual.
Main Results:
- Several high-priority phase 3 clinical trials are open or planned for prostate cancer.
- Systemic therapy research is vital for earlier disease stages and novel targeted agents.
- Lagging accrual rates pose a significant challenge to advancing prostate cancer research.
Conclusions:
- Enrollment in national phase 3 clinical trials is critical for answering key questions in prostate cancer management.
- Improved accrual strategies are needed to facilitate the timely completion of vital research.
- Further investigation of chemotherapy and novel targeted therapies is essential for all stages of prostate cancer progression.